Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 6/20 | 0.71 |
| ▸ | FYN | P06241 | 2/20 | 0.50 |
| ▸ | JAK2 | O60674 | 4/20 | 0.47 |
| ▸ | MPO | P05164 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL487619 | 1.00 | MET (0.71) | METFYNJAK2MPOCYP3A4 | |
| SCHEMBL488042 | 0.90 | MET (0.79) | METFYNJAK2MPOMAP4K3 | |
| SCHEMBL487572 | 0.88 | MET (0.73) | METFYNJAK2MPOMAP4K3 | |
| SCHEMBL487907 | 0.88 | MET (0.81) | METFYNJAK2MPOMAP4K3 | |
| SCHEMBL487624 | 0.88 | MET (0.72) | METFYNJAK2MPOMAP4K3 | |
| SCHEMBL30453540 | 0.88 | MET (0.72) | METFYNJAK2MPOMAP4K3 | |
| SCHEMBL487730 | 0.87 | MET (0.79) | METFYNJAK2MPOMAP4K3 | |
| SCHEMBL30454723 | 0.87 | MET (0.79) | METFYNJAK2MPOMAP4K3 | |
| Water SCHEMBL28121971 | 0.87 | MET (0.79) | METFYNJAK2MPOMAP4K3 | |
| SCHEMBL488145 | 0.85 | MET (0.68) | METJAK2MAP4K3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113181362-B | Medicament for preventing and/or treating amyotrophic lateral sclerosis | 国立大学法人京都大学 | 2023-06-13 | — | — | CN | disclosed |